Esder Lee1, Gyeong Ryul Ryu1, Seung-Hyun Ko1, Yu-Bae Ahn1, Ki-Ho Song2. 1. Division of Endocrinology & Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 2. Division of Endocrinology & Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Electronic address: kihos@catholic.ac.kr.
Abstract
OBJECTIVES: To investigate whether the activation of pancreatic stellate cells (PSCs) leads to pancreatic β-cell dysfunction in type 2 diabetes mellitus (T2DM). METHODS: The pancreases of Otsuka Long-Evans Tokushima Fatty (OLETF) rats, an animal model of T2DM, and patient with T2DM were analyzed. And the in vitro and in vivo effects of pirfenidone, an antifibrotic agent, on PSC activation, islet fibrosis, and β-cells were studied. RESULTS: The extent of islet fibrosis and the percentage of activated PSCs, positive for α-smooth muscle actin, in the islets were significantly greater in OLETF rats compared with non-diabetic rats. Also, the extent of islet fibrosis in patients with T2DM was slightly greater compared with age- and BMI-matched non-diabetic patients. In rat PSCs cultured with high glucose for 72 h, pirfenidone produced decreases in cell proliferation, release of collagen, and the expression of fibronectin and connective tissue growth factor. Treatment of OLETF rats with pirfenidone for 16 weeks decreased the activation of PSCs and the extent of islet fibrosis, but did not enhance glucose tolerance, pancreatic insulin content, or β-cell mass. CONCLUSIONS: Activated PSCs in islets might lead to islet fibrosis in T2DM. However, PSC activation itself might not contribute significantly to progressive β-cell failure in T2DM.
OBJECTIVES: To investigate whether the activation of pancreatic stellate cells (PSCs) leads to pancreatic β-cell dysfunction in type 2 diabetes mellitus (T2DM). METHODS: The pancreases of Otsuka Long-Evans Tokushima Fatty (OLETF) rats, an animal model of T2DM, and patient with T2DM were analyzed. And the in vitro and in vivo effects of pirfenidone, an antifibrotic agent, on PSC activation, islet fibrosis, and β-cells were studied. RESULTS: The extent of islet fibrosis and the percentage of activated PSCs, positive for α-smooth muscle actin, in the islets were significantly greater in OLETFrats compared with non-diabeticrats. Also, the extent of islet fibrosis in patients with T2DM was slightly greater compared with age- and BMI-matched non-diabeticpatients. In rat PSCs cultured with high glucose for 72 h, pirfenidone produced decreases in cell proliferation, release of collagen, and the expression of fibronectin and connective tissue growth factor. Treatment of OLETFrats with pirfenidone for 16 weeks decreased the activation of PSCs and the extent of islet fibrosis, but did not enhance glucose tolerance, pancreatic insulin content, or β-cell mass. CONCLUSIONS: Activated PSCs in islets might lead to islet fibrosis in T2DM. However, PSC activation itself might not contribute significantly to progressive β-cell failure in T2DM.
Authors: Laura K Cole; Prasoon Agarwal; Christine A Doucette; Mario Fonseca; Bo Xiang; Genevieve C Sparagna; Nivedita Seshadri; Marilyne Vandel; Vernon W Dolinsky; Grant M Hatch Journal: Endocrinology Date: 2021-07-01 Impact factor: 4.736
Authors: Wei Xu; Jun Liang; H F Geng; Jun Lu; Rui Li; X L Wang; Qian Lv; Ying Liu; Jie Wang; X K Liu; Peter M Jones; Zl Sun Journal: Int J Endocrinol Date: 2019-04-11 Impact factor: 3.257
Authors: Yunting Zhou; Junming Zhou; Bo Sun; Wei Xu; Ming Zhong; Yumin Li; Cong He; Yang Chen; Xiaohang Wang; Peter M Jones; Zilin Sun Journal: Int J Biol Sci Date: 2020-01-30 Impact factor: 6.580